ANI Pharmaceuticals, Inc. (NASDAQ:ANIP) Shares Sold by Comerica Bank

Comerica Bank reduced its holdings in shares of ANI Pharmaceuticals, Inc. (NASDAQ:ANIP - Free Report) by 30.1% during the fourth quarter, according to its most recent disclosure with the Securities and Exchange Commission (SEC). The fund owned 18,830 shares of the specialty pharmaceutical company's stock after selling 8,099 shares during the period. Comerica Bank owned about 0.09% of ANI Pharmaceuticals worth $1,041,000 at the end of the most recent reporting period.

A number of other institutional investors and hedge funds have also bought and sold shares of ANIP. Dimensional Fund Advisors LP grew its holdings in shares of ANI Pharmaceuticals by 4.6% in the fourth quarter. Dimensional Fund Advisors LP now owns 685,730 shares of the specialty pharmaceutical company's stock worth $37,906,000 after purchasing an additional 30,420 shares during the last quarter. Global Alpha Capital Management Ltd. grew its holdings in shares of ANI Pharmaceuticals by 16.4% in the fourth quarter. Global Alpha Capital Management Ltd. now owns 624,550 shares of the specialty pharmaceutical company's stock worth $34,525,000 after purchasing an additional 88,100 shares during the last quarter. William Blair Investment Management LLC grew its holdings in shares of ANI Pharmaceuticals by 2.2% in the fourth quarter. William Blair Investment Management LLC now owns 485,268 shares of the specialty pharmaceutical company's stock worth $26,826,000 after purchasing an additional 10,440 shares during the last quarter. Geode Capital Management LLC grew its holdings in shares of ANI Pharmaceuticals by 0.9% in the fourth quarter. Geode Capital Management LLC now owns 428,999 shares of the specialty pharmaceutical company's stock worth $23,720,000 after purchasing an additional 3,774 shares during the last quarter. Finally, Assenagon Asset Management S.A. grew its holdings in shares of ANI Pharmaceuticals by 67.4% in the fourth quarter. Assenagon Asset Management S.A. now owns 311,617 shares of the specialty pharmaceutical company's stock worth $17,226,000 after purchasing an additional 125,438 shares during the last quarter. 76.05% of the stock is currently owned by institutional investors.

Analysts Set New Price Targets

ANIP has been the topic of several recent analyst reports. JPMorgan Chase & Co. initiated coverage on shares of ANI Pharmaceuticals in a report on Wednesday, March 12th. They issued an "overweight" rating and a $85.00 target price on the stock. Jefferies Financial Group assumed coverage on shares of ANI Pharmaceuticals in a report on Friday, March 14th. They issued a "buy" rating and a $80.00 price target on the stock. Truist Financial boosted their price objective on shares of ANI Pharmaceuticals from $62.00 to $65.00 and gave the company a "hold" rating in a research report on Monday, April 21st. Guggenheim restated a "buy" rating and issued a $86.00 price objective on shares of ANI Pharmaceuticals in a report on Monday, May 12th. Finally, HC Wainwright reaffirmed a "buy" rating and issued a $94.00 target price on shares of ANI Pharmaceuticals in a research report on Monday, March 17th. One analyst has rated the stock with a sell rating, one has issued a hold rating, seven have given a buy rating and one has given a strong buy rating to the company. According to MarketBeat, the stock has an average rating of "Moderate Buy" and an average price target of $80.13.

ANI Pharmaceuticals Stock Performance

ANIP stock traded up $0.46 during trading on Friday, reaching $59.99. The company had a trading volume of 372,976 shares, compared to its average volume of 298,906. The firm has a 50-day simple moving average of $66.91 and a 200-day simple moving average of $60.79. The company has a market cap of $1.31 billion, a price-to-earnings ratio of -109.07 and a beta of 0.56. The company has a debt-to-equity ratio of 1.52, a quick ratio of 1.97 and a current ratio of 2.74. ANI Pharmaceuticals, Inc. has a twelve month low of $52.50 and a twelve month high of $77.00.

ANI Pharmaceuticals (NASDAQ:ANIP - Get Free Report) last posted its quarterly earnings results on Friday, May 9th. The specialty pharmaceutical company reported $1.70 earnings per share (EPS) for the quarter, topping analysts' consensus estimates of $1.37 by $0.33. ANI Pharmaceuticals had a negative net margin of 1.28% and a positive return on equity of 15.87%. The company had revenue of $197.12 million during the quarter, compared to analyst estimates of $179.75 million. During the same period last year, the firm posted $0.82 EPS. ANI Pharmaceuticals's revenue for the quarter was up 43.4% compared to the same quarter last year. As a group, sell-side analysts expect that ANI Pharmaceuticals, Inc. will post 3.86 earnings per share for the current year.

Insiders Place Their Bets

In other news, insider Christopher Mutz sold 4,000 shares of ANI Pharmaceuticals stock in a transaction that occurred on Wednesday, May 14th. The shares were sold at an average price of $60.45, for a total transaction of $241,800.00. Following the completion of the transaction, the insider now directly owns 107,317 shares of the company's stock, valued at $6,487,312.65. The trade was a 3.59% decrease in their position. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available through the SEC website. Also, SVP Ori Gutwerg sold 881 shares of ANI Pharmaceuticals stock in a transaction that occurred on Thursday, May 15th. The shares were sold at an average price of $60.07, for a total transaction of $52,921.67. Following the transaction, the senior vice president now directly owns 89,897 shares of the company's stock, valued at approximately $5,400,112.79. This trade represents a 0.97% decrease in their ownership of the stock. The disclosure for this sale can be found here. In the last ninety days, insiders sold 7,681 shares of company stock valued at $468,698. 11.10% of the stock is owned by insiders.

ANI Pharmaceuticals Company Profile

ANI Pharmaceuticals, Inc, a biopharmaceutical company, develops, manufactures, and markets branded and generic prescription pharmaceuticals in the United States and Canada. The company manufactures oral solid dose products; semi-solids, liquids, and topicals; controlled substances; and potent products, as well as performs contract development and manufacturing of pharmaceutical products.